tradingkey.logo

Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study Of RDX-002 In Post-GLP-1 Management

ReutersAug 13, 2025 1:02 PM

-

  • RESPONSE PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF RDX-002 IN POST-GLP-1 MANAGEMENT

  • RESPONSE PHARMACEUTICALS: STUDY'S PRIMARY ENDPOINT MET

  • RESPONSE PHARMACEUTICALS: STUDY'S MULTIPLE SECONDARY ENDPOINTS MET INCLUDING STATISTICALLY SIGNIFICANT REDUCTION IN WEIGHT REGAIN (-34%) VERSUS PLACEBO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI